Powles, Thomas
Choueiri, Toni K.
Motzer, Robert J.
Jonasch, Eric
Pal, Sumanta
Tannir, Nizar M.
Signoretti, Sabina
Kaldate, Rajesh
Scheffold, Christian
Wang, Evelyn
Aftab, Dana T.
Escudier, Bernard
George, Daniel J.
Article History
Received: 30 March 2021
Accepted: 16 July 2021
First Online: 7 August 2021
Change Date: 15 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12885-021-08693-9
Declarations
:
: The study adhered to the Good Clinical Practice guidelines, the Declaration of Helsinki, and all applicable local laws and regulatory requirements. The study protocol was approved by the institutional review board or ethics committee of all participating centers (the names of the institutional review boards or ethics committees are provided in the InternalRef removed). All patients provided written informed consent.
: Not applicable.
: Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche.Dr. Choueiri has consulting relationships with AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly and Company, EMD Serono, Exelixis, GlaxoSmithKline, Merck, Novartis, and Pfizer; has received institutional research grants from Bristol-Myers Squibb, Exelixis, and GlaxoSmithKline; has received travel fees from Bristol-Myers Squibb, Eisai, Eli Lilly and Company, Exelixis, Merck, Novartis, and Pfizer; and has stock in Pionyr and Tempest.Dr. Motzer has received grants from Eisai, Pfizer, Novartis, Exelixis, Genentech, Roche, and Bristol Myers Squibb; and has received personal fees from Eisai, Merck, Pfizer, Novartis, Exelixis, Genentech, Incyte, Lilly, Roche, Bristol Myers Squibb, Astra Zeneca, and EMD Serono.Dr. Jonasch has received grants from Exelixis, Aravive, Merck, and Novartis; and has received personal fees from Exelixis, Aravive, Eisai, Calithera, Merck, Novartis, and Pfizer.Dr. Pal has a consulting or advisory role with Astellas Pharma, Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Ipsen, Myriad Pharmaceuticals, Novartis, and Pfizer; and has received research funding from Medivation.Dr. Tannir has a consulting or advisory role with Bristol-Myers-Squibb, Pfizer, Nektar Therapeutics, Exelixis, Inc., Eisai Medical Research, Eli Lilly, Oncorena, Ono Pharmaceutical, Calithera Bioscience, Surface Oncology, Novartis, Ipsen, and Merck Sharp & Dohme; has received research funding from Bristol-Myers-Squibb, Pfizer, Nektar Therapeutics, Exelixis, Inc., Calithera Bioscience, Mirati Therapeutics, Epizyme Inc., Lilly, Arrowhead Pharmaceuticals, Inc., Takeda, and Eisai; and is on scientific advisory committees with Nektar Therapeutics, Pfizer, Oncorena, Eli Lilly, and Eisai Medical Research.Dr. Signoretti has a consulting or advisory role with AstraZeneca/MedImmune, Bristol-Myers Squibb, and Merck; has received institutional research funding from AstraZeneca, Bristol-Myers Squibb, Exelixis, and Novartis; has received royalties from Biogenex.Dr. Kaldate is a former employee of Exelixis; has stock/ownership interests with Exelixis.Dr. Scheffold is employed by Exelixis; has stock/ownership interests with Exelixis; and has a patent.Dr. Wang is a former employee of Exelixis; has stock/ownership interests with Exelixis.Dr. Aftab is employed by Exelixis; has stock/ownership interests with Exelixis; and has a patent.Dr. Escudier has received grants from BMS, Novartis, and Aveo; and has received personal fees from BMS, Aveo, Ipsen, Pfizer, Oncorena, Immunicum, Novartis, and Roche.Dr. George is a senior editor for American Association of Cancer Research; is a co-editor-in-chief for Clin Adv Hematol Oncol (Millennium Medical Publishing); has a consulting or advisory role with Astellas, AstraZeneca, Bayer Pharmaceuticals, Bristol Myers Squibb (BMS), Constellation Pharma, Exelixis, Inc., Flatiron, Janssen Pharma, Merck Sharp & Dohme, Michael J Hennessey Assoc, Myovant Sciences, Inc., Physician Education Resource, LLC, Pfizer, Propella Therapeutics, Revhealth, LLC, Sanofi, and Vizuri Health Sciences; has been on advisory boards for Astellas, AstraZeneca, Capio Biosciences, and Modra Pharma; has received institutional research grants from Astellas, BMS, Calithera, Exelixis, Inc., Janssen Pharma, Novartis, Pfizer, and Sanofi; has been a steering committee member for AstraZeneca, NCI Genitourinary, and Nektar Therapeutics; has been an independent contractor with Axess Oncology; has been a speaker for Bayer Pharmaceuticals, Exelixis, Inc., and Sanofi; has served on a speakers’ bureau for Exelixis, Inc.; has received honoraria from EMD Serono, Ipsen, Michael J Hennessey Assoc, UroGPO, and UroToday; and has received travel accommodation fees from Bayer Pharmaceuticals, Exelixis, Inc., Sanofi, and UroToday.